Skip to main content
SpringerLink
Log in

Anoro Ellipta set to change COPD prescribing

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. LaunchTrends Anoro Ellipta (Wave 1) 2014

  2. long-acting beta-agonist/long-acting muscarinic antagonist

Reference

  • Decision Resources Group. GlaxoSmithKline/Theravance’s Anoro Ellipta is Most Likely to Replace Boehringer Ingelheim’s Spiriva Among COPD Patients, According to U.S. Pulmonologists. Media Release : 26 Aug 2014. Available from: URL: http://www.decisionresourcesgroup.com

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anoro Ellipta set to change COPD prescribing. PharmacoEcon Outcomes News 711, 33 (2014). https://doi.org/10.1007/s40274-014-1542-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1542-3

Search

Navigation